Hikma Pharmaceuticals PLC Share Price

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. 16:35:26 14/06/2024 BST 5-day change 1st Jan Change
1,958 GBX -1.81% Intraday chart for Hikma Pharmaceuticals PLC +0.46% +9.45%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.99B 236B Sales 2025 * 3.09B 243B Capitalization 5.51B 434B
Net income 2024 * 414M 32.64B Net income 2025 * 451M 35.56B EV / Sales 2024 * 2.13 x
Net Debt 2024 * 852M 67.22B Net Debt 2025 * 607M 47.85B EV / Sales 2025 * 1.98 x
P/E ratio 2024 *
13.6 x
P/E ratio 2025 *
12.4 x
Employees 9,100
Yield 2024 *
2.88%
Yield 2025 *
3.05%
Free-Float 65.59%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hikma Pharmaceuticals PLC

1 day-1.81%
1 week+0.46%
Current month+1.45%
1 month-2.20%
3 months+4.99%
6 months+9.97%
Current year+9.45%
More quotes
1 week
1 913.00
Extreme 1913
2 020.00
1 month
1 857.00
Extreme 1857
2 034.00
Current year
1 750.00
Extreme 1750
2 165.00
1 year
1 711.00
Extreme 1711
2 222.00
3 years
1 174.50
Extreme 1174.5
2 703.00
5 years
1 174.50
Extreme 1174.5
2 768.00
10 years
814.20
Extreme 814.2
2 768.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 31/12/89
Director of Finance/CFO 52 31/12/00
Chairman 67 31/12/80
Members of the board TitleAgeSince
Director/Board Member 67 30/04/20
Director/Board Member 72 30/09/16
Director/Board Member 62 31/10/22
More insiders
Date Price Change Volume
14/06/24 1,958 -1.81% 199,146
13/06/24 1,994 -0.80% 179,333
12/06/24 2,010 +1.88% 304,406
11/06/24 1,973 +2.23% 360,418
10/06/24 1,930 -0.97% 175,673

Delayed Quote London S.E., June 14, 2024 at 04:35 pm

More quotes
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.83 USD
Average target price
28.76 USD
Spread / Average Target
+15.81%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW